|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, whether serum glycosylation isomer of M2BP (M2BPGi) was associated with the regression of liver fibrosis in patients with chronic hepatitis B (CHB) during IFN-α add-on therapy is still unknown.
|
30905065 |
2019 |
|
LGALS3BP
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interferon-λ3 levels were significantly higher after viral clearance in patients who developed HCC and were associated with a higher potential for hepatocarcinogenesis, such as a higher frequency of non-hypervascular hypointensive nodules (P = 0.046), higher stages of liver fibrosis (P < 0.001), and higher post-treatment levels of Wisteria floribunda agglutinin positive Mac-2 binding protein (P < 0.001) and alanine aminotransferase (P < 0.001).
|
30623518 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum diagnostic marker for liver fibrosis in various liver diseases.
|
30671807 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
M2BP was measured in 31 HIV/HCV co-infected patients, and we analyzed the correlation between WFA<sup>+</sup> -M2BP and several markers of fibrosis, liver function, and tumor markers.
|
31785125 |
2019 |
|
LGALS3BP
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate WFA+-M2BP level in assessing liver fibrosis in patients with chronic hepatitis B (CHB) infection.
|
31393964 |
2019 |
|
LGALS3BP
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In AIH group, serum galectin-9 levels weakly correlated with alanine aminotransferase levels or total bilirubin (TB) and strongly correlated with C-X-C motif chemokine 10 (CXCL10) and Mac-2 binding protein glycosylation isomer (M2BPGi) levels, but did not correlate with the histological grade of liver fibrosis.
|
31464928 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel marker for liver fibrosis.
|
30786068 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mac-2 binding protein glycosylation isomer (M2BPGi) is a reliable and non-invasive marker for assessing liver fibrosis.
|
31339606 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, the patients in the higher value group had significantly worse prognosis after NASH diagnosis CONCLUSION: AKR1B10 is a useful serum biomarker for advanced liver fibrosis in NASH and, combined with serum WFA(+)-M2BP, can predict HCC development, gastroesophageal varix formation, and poor prognosis.
|
30707282 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis.
|
31392502 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA<sup>+</sup> -M2BP) is a novel marker for staging liver fibrosis and predicting hepatocellular carcinoma (HCC) occurrence.
|
29732647 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to assess the association between the serum glycobiomarker Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA<sup>+</sup>-M2BP) for liver fibrosis and outcomes and carcinogenesis of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients with advanced fibrosis.
|
29491234 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mac-2-binding protein glycosylation isomer (M2BPGi) was recently identified as a serum glycobiomarker for liver fibrosis.
|
29473206 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA<sup>+</sup> -M2BP) is a novel glycobiomarker for evaluating liver fibrosis, but less is known about its role in liver cirrhosis (LC).
|
29607614 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
The WFA<sup>+</sup> -M2BP values were significantly greater in NAFLD patients with HCC than in those without HCC among patients with liver fibrosis ≥stage 3.
|
29316028 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
We showed that serum WFA<sup>+</sup> -M2BP or type IV collagen 7S levels serve as useful independent markers for detecting significant fibrosis and that use of both WFA<sup>+</sup> -M2BP and type IV collagen 7S together increased the sensitivity and negative predictive value for the diagnosis of liver fibrosis.
|
29633352 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
For predicting cirrhosis (F4) and advanced liver fibrosis (≥ F3), M2BPGi had higher areas under the curve (AUCs; 0.93, respectively) with cutoff COIs of 1.84 and 1.67, respectively, than for the four conventional markers for fibrosis.
|
30128700 |
2018 |
|
LGALS3BP
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A glycoproteomics study aimed at identifying such markers discovered Mac 2-Binding Protein Gylcan Isomer (M2BPGi), which is a reliable marker for assessing liver fibrosis in patients with viral hepatitis and other fibrotic liver diseases such as primary biliary cholangitis, biliary atresia, autoimmune hepatitis, and nonalcoholic fatty liver disease.
|
29318378 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
This head-to-head comparison suggests that WFA<sup>+</sup> -M2BP is superior to M2BP for distinguishing liver fibrosis stages in NAFLD patients.
|
29274190 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mac-2-binding protein glycosylation isomer (M2BPGi), a novel serum marker for liver fibrosis, was seldom studied in chronic hepatitis B (CHB).
|
29915243 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA<sup>+</sup> -M2BP) is a novel serum marker of hepatic fibrosis in adults with chronic hepatitis C. However, it remains unclear whether serum WFA<sup>+</sup> -M2BP levels are associated with the progression of liver histology in primary sclerosing cholangitis (PSC).
|
29168311 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
We explored the usefulness of four novel biomarkers, enhanced liver fibrosis (ELF), glycosylation isomer of Mac-2 binding protein (M2BPGi), galectin-3, and soluble suppression of tumorigenicity 2 (sST2), in association with liver fibrosis.
|
29611383 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
WFA-M2BP can support a diagnosis of liver fibrosis with similar diagnostic efficacy to other biomarkers, and predicted liver fibrosis stage ≥2 among patients with chronic hepatitis B.
|
29611385 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA<sup>+</sup> -M2BP) can be used to assess the degree of liver fibrosis, but few studies have investigated its prognostic utility.
|
27973711 |
2017 |
|
LGALS3BP
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Linear regression analysis revealed that alanine aminotransferase (odds ratio [OR]: 0.03, 95% confidence intervals [CI]: 0.02-0.05, P < 0.001), AST (OR: -0.1, 95% CI: -0.02 to -0.01, P < 0.001), and liver fibrosis (OR: 0.30, 95% CI: 0.01-0.59, P = 0.043) were the independent factors correlated to serum WFA<sup>+</sup>-M2BP level.
|
28811008 |
2017 |